|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | European Organization for Research and Treatment of Cancer |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00003938 |
Purpose
RATIONALE: Liposomal amphotericin B may be effective in controlling fever and granulocytopenia. It is not yet known which regimen of liposomal amphotericin B is more effective in treating cancer patients who have these conditions.
PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of liposomal amphotericin B in treating granulocytopenia and fever in cancer patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Cancer |
Drug: liposomal amphotericin B |
Phase III |
| Study Type: | Interventional |
| Study Design: | Supportive Care, Randomized, Active Control |
| Official Title: | A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials |
| Estimated Enrollment: | 450 |
| Study Start Date: | June 1999 |
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to antifungal prophylaxis (yes vs no) and type of underlying condition. Patients are randomized to 1 of 2 treatment arms.
Treatment continues until signs and symptoms of the fungal infection appear or febrile neutropenia has resolved. Persistently neutropenic patients receive treatment for at least 10 days or until another cause of infection is determined.
Patients are followed weekly for 3 weeks.
PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Contacts and Locations
Hide Study Locations| Belgium | |
| A.Z. St. Jan | |
| Brugge, Belgium, 8000 | |
| Clinique Universitaire De Mont-Godinne | |
| Mont-Godinne Yvoir, Belgium, 5530 | |
| Hopital Universitaire Erasme | |
| Brussels, Belgium, 1070 | |
| Institut Jules Bordet | |
| Brussels, Belgium, 1000 | |
| U.Z. Gasthuisberg | |
| Leuven, Belgium, B-3000 | |
| Czech Republic | |
| University Hospital - Olomouc | |
| Olomouc, Czech Republic, 775 20 | |
| France | |
| Centre Hospitalier Universitaire Henri Mondor | |
| Creteil, France, 94010 | |
| CHU de Caen | |
| Caen, France, 14033 | |
| Hopital Saint-Louis | |
| Paris, France, 75475 | |
| Germany | |
| Universitaetsklinikum Charite | |
| Berlin, Germany, D-10117 | |
| Virchow Klinikum Humboldt Universitaet Berlin | |
| Berlin, Germany, D-13353 | |
| Greece | |
| Athens University-Laikon General Hospital | |
| Athens, Greece, 11527 | |
| Hippokration Hospital | |
| Thessaloniki, Greece, 54642 | |
| Hungary | |
| Szent Laszlo Korhaz | |
| Budapest, Hungary, 1097 | |
| Israel | |
| Hadassah University Hospital | |
| Jerusalem, Israel, 91120 | |
| Italy | |
| Istituto Nazionale per la Ricerca sul Cancro | |
| Genoa (Genova), Italy, 16132 | |
| Netherlands | |
| University Medical Center Nijmegen | |
| Nijmegen, Netherlands, NL-6500 HB | |
| Portugal | |
| Hospital De Santo Antonio Dos Capuchos | |
| Lisbon (Lisboa), Portugal, 1100 | |
| Slovakia | |
| National Cancer Institute - Bratislava | |
| Bratislava, Slovakia, 812 50 | |
| Spain | |
| Hospital Central de Asturias | |
| Oviedo, Spain, 33006 | |
| Hospital de la Santa Cruz I Sant Pau | |
| Barcelona, Spain, 08025 | |
| Sweden | |
| Huddinge University Hospital | |
| Stockholm, Sweden, SE-141 86 | |
| Turkey | |
| Section of Infectious Diseases | |
| Ankara, Turkey, 06100 | |
| United Arab Emirates | |
| Tawam Hospital | |
| Abu Dhabi, United Arab Emirates | |
| Study Chair: | P. Ljungman, MD | Karolinska University Hospital - Huddinge |
More Information
| Study ID Numbers: | CDR0000067130, EORTC-19951 |
| Study First Received: | November 1, 1999 |
| Last Updated: | November 16, 2008 |
| ClinicalTrials.gov Identifier: | NCT00003938 History of Changes |
| Health Authority: | United States: Federal Government |
|
stage I adult Hodgkin lymphoma stage II adult Hodgkin lymphoma stage III adult Hodgkin lymphoma stage IV adult Hodgkin lymphoma stage IV breast cancer stage IIIA breast cancer monoclonal gammopathy of undetermined significance stage IIIB breast cancer recurrent childhood acute lymphoblastic leukemia recurrent adult Hodgkin lymphoma stage I cutaneous T-cell non-Hodgkin lymphoma stage II cutaneous T-cell non-Hodgkin lymphoma stage III cutaneous T-cell non-Hodgkin lymphoma stage IV cutaneous T-cell non-Hodgkin lymphoma recurrent cutaneous T-cell non-Hodgkin lymphoma |
isolated plasmacytoma of bone extramedullary plasmacytoma refractory multiple myeloma recurrent childhood rhabdomyosarcoma stage II ovarian epithelial cancer stage III ovarian epithelial cancer stage IV ovarian epithelial cancer recurrent ovarian epithelial cancer disseminated neuroblastoma recurrent neuroblastoma recurrent Wilms tumor and other childhood kidney tumors stage 0 chronic lymphocytic leukemia Waldenstrom macroglobulinemia stage I multiple myeloma stage II multiple myeloma |
|
Abelcet Anti-Infective Agents Amphotericin B Antiprotozoal Agents Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Liposomal amphotericin B Pharmacologic Actions Anti-Bacterial Agents Lymphatic Diseases |
Antiparasitic Agents Neoplasms Antifungal Agents Therapeutic Uses Lymphoma, Large-Cell, Immunoblastic Antibiotics, Antifungal Amebicides Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma |